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Abstract
Autologous chondrocyte implantation (ACI) is the most widely
used cell-based surgical procedure for the repair of articular
cartilage defects. Challenges to successful ACI outcomes include
limitation in defect size and geometry as well as inefficient cell
retention. Second-generation ACI procedures have thus focused
on developing three-dimensional constructs using native and
synthetic biomaterials. Clinically significant and satisfactory results
from applying autologous chondrocytes seeded in fibrin within a
biodegradable polymeric material were recently reported. In the
future, third-generation cell-based articular cartilage repair should
focus on the use of chondroprogenitor cells and biofunctionalized
biomaterials for more extensive and permanent repair.
Introduction
The hyaline articular cartilage protects the bones of
diarthrodial joints from forces associated with load bearing,
friction, and impact. Despite its viscoelastic properties and
remarkable mechanical durability, once articular cartilage is
injured it has very limited capacities for self-repair. In full-
thickness cartilage injuries, in which there is damage to the
chondral layer and subchondral bone plate, blood vessel
rupture and hematoma formation are seen at the injury site.
Chondroprogenitor cells derived from the bone marrow
migrate to the lesion and initiate a repair process that results
in the formation of a fibrocartilage repair tissue [1,2]. On the
other hand, when the lesion is completely contained within
the avascular articular cartilage layer (partial thickness
defects), there is no involvement of the vasculature, and
blood and marrow cannot enter the damaged region to
influence or contribute to the reparative process. Resident
articular chondrocytes do not migrate to the lesion, and
production of a reparative matrix by these cells does not
occur. Thus, the defect is not filled or repaired and essentially
becomes permanent [1,2].
Cartilage repair
In focal cartilage defects, in which a stable fibrocartilaginous
repair tissue has not formed, the aim of surgical procedures is
to promote a natural fibrocartilaginous response by using
marrow stimulating techniques, such as abrasion arthroplasty,
Pridie drilling, or microfracture. These procedures are cost-
effective and clinically useful because patients often have
reduced pain and improved joint function, and they are
therefore generally considered first-line treatments for focal
cartilage defects [3-7].
Compared with normal hyaline articular cartilage, however,
fibrocartilage has inferior mechanical and biochemical
characteristics, is poorly organized, contains significant
amounts of collagen type I, and is susceptible to injury. The
breakdown of this inferior repair tissue with time and loading
eventually leads to premature osteoarthritis [1,2]. The aim of
contemporary surgical and therapeutic procedures is to
achieve a more hyaline-like cartilage repair tissue by trans-
planting tissues or cells.
Autologous chondrocyte implantation
Tissue transplantation procedures such as periosteum, peri-
chondrium, and osteochondral grafts have yielded positive
short-term results for a number of patients, but the long-term
clinical results are uncertain, with tissue availability for
transplant being a major limitation, especially in large
cartilage defects [2,3,8-10]. The autologous chondrocyte
implantation (ACI) procedure, first introduced by Brittberg
and coworkers [11] in 1994, has been the most widely used
surgical procedure (more than 15,000 treatments have been
performed). The ACI procedure involves the use of a peri-
osteal flap or a collagen sheet [12], which is fixed to the
surrounding cartilage to create a reservoir for injection of a
suspension of culture-expanded autologous chondrocytes. A
variety of clinical studies have documented the clinical
effectiveness of ACI-related procedures for the regeneration
of articular cartilage [13,14]. However, ACI application may
be impossible in certain areas of the joint because of
anatomic factors, and the fixation of the periosteal flap or
collagen sheets covering the chondrocyte suspension may
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be insecure, especially in degenerative defects that lack an
intact cartilage rim. Other potential complications reported
have included periosteal hypertrophy, ablation, uneven cell
distribution, and loss of cells into the joint cavity [15,16],
resulting in repetition of surgery in up to 25% to 36% of
patients [12,17].
Recent developments in autologous chondrocyte
implantation
Recent technologic improvements have aimed to overcome
the intrinsic technical disadvantages of ACI by using cartilage
tissue engineering grafts developed with three-dimensional
scaffolds or matrices that contain autologous chondrocytes
for cartilage regeneration. Biomaterials that have been used
include hyaluronan [18] and collagen type I [19], and safety
and effectiveness have been demonstrated for cartilage
repair [12]. Despite these advances, most surgical inter-
ventions only result in improvement in clinical symptoms, such
as pain relief, and the regeneration of long-lasting hyaline
cartilage repair tissue remains a significant challenge [2,13].
Therefore, tissue engineering approaches are being
aggressively investigated in an effort to engineer cartilage in
vitro to produce grafts that will facilitate regeneration of
articular cartilage in vivo. In most cases, chondrocytes or
chondroprogenitor cells are harvested by enzymatic digestion
or outgrowth culture methods, and then extensively expanded
in culture. The cells are then seeded into various biocom-
patible scaffolds and either further cultured under chondro-
genically favorable conditions or implanted immediately [20-22].
In a recent study, Ossendorf and coworkers [23] reported
favorable repair of focal articular cartilage defects using a
modification of ACI based on autologous polymer-based
three-dimensional chondrocyte grafts. The polymeric matrix
used in this study was BioSeed-C (a polyglycolic/polylactic
acid and polydioxane based material), and culture-expanded
autologous chondrocytes, suspended in fibrin, are seeded
and dispersed within the matrix. BioSeed-C is a proprietary
biomaterial marketed by Biotissue Technologies (Freiburg,
Germany) as a stable, resorbable, three-dimensional matrix
for tissue engineering, particularly for orthopedic and oral
applications.
Ossendorf and coworkers [23] evaluated the cell-seeded,
two-component, gel-polymer composite in the arthrotomic
and arthroscopic treatment of post-traumatic and degener-
ative cartilage defects in a group of patients suffering from
chronic post-traumatic or degenerative cartilage lesions of
the knee. Clinical outcome was assessed in 40 patients with
a 2-year clinical follow up before implantation and at 3, 6, 12,
and 24 months after implantation. Evaluations were based on
the modified Cincinnati Knee Rating System, the Lysholm
Score, the Knee Injury and Osteoarthritis Outcome Score,
and the current health assessment form (36-item Short Form)
of the International Knee Documentation Committee, as well
as histologic analysis of second-look biopsies. Significant
improvement (P < 0.05) in the evaluated scores and histo-
logically observed integration of the graft with the host
cartilage tissues were reported. These findings suggest that
implantation of autologous chondrocyte-seeded BioSeed-C
is an effective treatment option for the regeneration of post-
traumatic or osteoarthritic defects of the knee.
The findings reported by Ossendorf and coworkers [23]
demonstrate a number of advantages of this second-
generation ACI approach over the original procedure. Specifi-
cally, by using a stable, three-dimensional matrix, seeded
chondrocytes are retained more efficiently at the site of
implantation, which should promote integration between the
neo-cartilage and the surrounding host articular cartilage
tissue. A critical feature of the technology is the use of a gel
carrier for the seeded cells to perfuse into the three-
dimensional polymer scaffold [24,25], a method that
essentially anchors the cells within the mechanically stable
scaffold while providing an environment that has been shown
to enhance the chondrocyte phenotype [26]. It should be
noted that the report by Ossendorf and coworkers did not
provide details on the fabrication protocol of the tissue-
engineered cartilage graft. For example, the exact cell density
per volume of the construct was not given, and neither were
details of the pre-surgery culture expansion of chondrocytes.
It would have been helpful to present these details as well as
observable characteristics of the engineered tissue grafts, in
order to allow evaluation of which parameters are ultimately
important for favorable clinical outcomes.
In addition to favorable clinical scores, Ossendorf and
coworkers [23] also reported histologic results on second-
look biopsies after implantation of the gel-polymer based
chondrocyte graft BioSeed-C. The engineered graft showed
mostly hyaline cartilage with some fibrocartilage, and
presence of viable chondrocytes and absence of calcifica-
tion, apoptosis, necrosis, and formation of a fibrous repair
tissue. However, there was unevenness in the graft in terms
of matrix staining, suggesting that the neo-cartilage may not
be homogeneous, which could result in compromised
mechanical properties. It is noteworthy that the histologic
analysis was derived from 18% of the patients who under-
went second-look arthroscopy as a result of grinding,
catching, pain, or swelling of the knee, a rate comparable to
that in other studies reporting rates of revision surgery
between 0% and 25% [17]. Failure rate with the BioSeed-C
procedure was only 2.5% (2/79), which is considerably lower
than the 5% to 13% reported in the literature for first-
generation ACI [13,17]. The significantly reduced operating
time and the potential for arthroscopic application are
additional benefits of the procedure reported here.
Based on the available data, the BioSeed-C procedure repre-
sents a potentially significant improvement of the current ACI
approach. In particular, the improvement in graft fixation
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focal lesions, which currently are the sole indication for ACI.
Compared with the use of native matrix materials alone, such
as collagen and hyaluronan, the cells are better retained in
the mechanically more stable BioSeed-C procedure. Another
advantage is that no cover material, such as the periosteum
used in the original ACI procedure, is required. It should be
noted that in the study conducted by Ossendorf and
coworkers [23] no specific selection of osteoarthritic patients
was conducted using the more standard International
Cartilage Repair Society [27] scoring system, and the
classification of osteoarthritis was done primarily based on
radiographic observations. A more targeted study in patients
with defined osteoarthritis is clearly required to test the
applicability of the BioSeed-C procedure for larger sized
cartilage repair of osteoarthritic lesions. Further development
of the technology described here to repair severe
osteoarthritic joints will require the following: a longer term
assessment of the biological and clinical outcomes; a better
definition of the cellularity requirement of functional cartilage
development; and evaluation of potential harmful effects of
local acidosis caused by degradation of the biomaterial.
Another potential improvement with second-generation ACI is
the application of chondroprogenitor cells, for example adult
tissue-derived mesenchymal stem cells, instead of articular
chondrocytes, in order to minimize additional donor site
morbidity caused by cartilage harvesting. To accomplish this,
the scaffold used must also serve the purpose of delivering
chondro-inductive factors and signals.
Conclusion
Cell-based grafts represent a promising approach to articular
cartilage repair, exemplified by ACI and related techniques.
From a biological perspective, the preferred features of the
graft material would include not only a three-dimensional
environment that supports cellular phenotype and
biocompatibility (specifically, with no signs of cytotoxicity,
apoptosis, and senescence) but also the storage and release
of factors supporting one or more biological aspects of
repair. Such biomaterials would constitute the third-
generation scaffolds, which will be capable of delivering, in a
programmed manner, biofactors or gene therapeutic reagents
in sufficient quantities and in a temporally specific manner to
induce a favorable chondrogenic response in the seeded
cells and in cells of the host tissue, and to inhibit local or
systemic tissue degenerative activities. Ultimately, guided
biomaterial development focusing on cell and cartilage tissue
specific requirements, including the biomechanical stability of
the matrix, kinetics of resorption, selection of bioactive factor,
cellular target(s), and mechanism of stimulation, should be
adopted for optimal cartilage regeneration.
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